Search PubMed⌕ Search

Biomedical subjects

K Lees

Publications and source records attributed to K Lees.

9 recordsLinked to original sources

Treating the acute stroke patient as an emergency: current practices and future opportunities.

Developments in acute stroke therapy have followed advances in the understanding of the evolving pathophysiology in both ischaemic stroke and intracerebral haemorrhage (ICH). In ischaemic stroke, rapid reperfusion of the ischaemic penumbra with thrombolysis within 3 h of symptom onset is of proven benefit, but few patients currently receive therapy, mainly due to the short-time window and lack of stroke expertise. In ICH, a recent study indicated that a haemostatic agent can limit ongoing bleeding and improve outcomes when administered within 4 h of stroke onset. These advances in acute stroke therapy underlie the concept that 'time is brain' and that urgent intervention can limit cerebral damage. Neuroprotective therapy could offer the prospect of a greater proportion of stroke patients receiving treatment, potentially before imaging and even in the ambulance setting. Virtually all stroke patients would benefit from receiving multidisciplinary care in acute stroke units.

Emergencies↗

CHHIPS (Controlling Hypertension and Hypotension Immediately Post-Stroke) Pilot Trial: rationale and design.

RATIONALE: High and low blood pressure (BP) levels are common following acute stroke, with up to 60% of patients being hypertensive (SBP > 160 mmHg) and nearly 20% having relative hypotension (SBP < or = 140 mmHg), within the first few hours of ictus, both conditions being associated with an adverse prognosis. At present, the optimum management of blood pressure in the immediate post-stroke period is unclear. OBJECTIVE: The primary aim of the Controlling Hypertension and Hypotension Immediately Post-Stroke (CHHIPS) Pilot Trial is to assess whether hypertension and relative hypotension, manipulated therapeutically in the first 24 h following acute stroke, affects short-term outcome measures. DESIGN: The CHHIPS Pilot Trial is a UK based multi-centre, randomized, double-blind, placebo-controlled, titrated dose trial. SETTING: Acute stroke and medical units in teaching and district general hospitals, in the UK. PATIENTS: The CHHIPS Pilot Study aims to recruit 2050 patients, with clinically suspected stroke, confirmed by brain imaging, who have no compelling indication or contraindication for BP manipulation. STUDY OUTCOMES: The primary outcome measure will be the effects of acute pressor therapy (initiated < or = 12 h from stroke onset) or depressor therapy (started < or = 24 h post-ictus) on death and dependency at 14 days post-stroke. Secondary outcome measures will include the influence of therapy on early neurological deterioration, the effectiveness of treatment in manipulating BP levels, the influence of time to treatment and stroke type on response and a cost-effectiveness analysis.

Acute Disease↗

Perindopril reduces blood pressure but not cerebral blood flow in patients with recent cerebral ischemic stroke.

BACKGROUND AND PURPOSE: The relationship between high blood pressure and the incidence of stroke is well established. Currently the effects of lowering blood pressure in patients with established cerebrovascular disease is undetermined, and there is continuing concern regarding the treatment of patients soon after a stroke event. Angiotensin-converting enzyme inhibitors maintain cerebral blood flow despite lowering blood pressure in patients with heart failure and otherwise uncomplicated hypertension. We tested the hypothesis that perindopril, an angiotensin-converting enzyme inhibitor with a gradual onset of action and a minimal first-dose hypotensive effect, lowers blood pressure without adversely affecting cerebral blood flow in patients 2 to 7 days after symptoms of cerebral infarction. METHODS: Patients were randomized to receive 15 days of oral perindopril (4 mg) or placebo in a double-blind study. Blood pressure was monitored semiautomatically. Cerebral blood flow was calculated from internal carotid artery and vertebral Doppler ultrasound, supplemented by middle cerebral artery blood velocities. RESULTS: Twenty-four patients completed the protocol; four additional patients were withdrawn for reasons unrelated to treatment. Patients on perindopril had a placebo-corrected reduction in blood pressure of 19/11 mm Hg. Blood pressure remained reduced after 2 weeks of treatment. In contrast, total cerebral blood flow was unaffected by perindopril. Neurological symptoms improved similarly in both groups. CONCLUSIONS: Perindopril was well tolerated and effectively reduced blood pressure without reducing carotid territory blood flow in patients with symptoms of recent cerebral ischemia.

Aged↗

Stroke.

Explore the source record for details and available documents.

Cerebrovascular Disorders↗

Immunochemical and enzymatic analyses of extracts of the house dust mite Dermatophagoides pteronyssinus.

The allergenicity and enzyme content of extracts of Dermatophagoides pteronyssinus whole mite, cuticle (CUT), and spent-growth medium (SGM) used in its culture have been examined. Both direct RAST binding and RAST-inhibition studies demonstrated that the whole mite extract was approximately threefold more potent than either the CUT or SGM extracts. Crossed immunoelectrophoresis and crossed radioimmunoelectrophoresis demonstrated that whole mite extracts contained 36 antigens of which nine were judged to be allergens (Dpt 1, 3, 4, 7, 8, 12, 17, 22, and 31). In contrast, extracts of CUT and SGM both contained 15 mite antigens of which five were judged to be allergens (Dpt 4, 8, 12, 17, and 22). Enzyme studies demonstrated that whole mite extracts from various sources contained esterases, phosphatases, aminopeptidases, and glycosidases. Both the CUT and SGM extracts contained a similar spectrum of enzymes, although the glycosidases were present at relatively low levels. Combined crossed immunoelectrophoresis and enzymic studies identified three antigens (Dpt 6, 13, and 24) with esterase activity, one antigen (Dpt 27) with beta-glucuronidase activity, and one antigen (Dpt 14) with acid phosphatase activity. Thus far, none of these enzymes has been demonstrated to be allergenic. Both enzymic and immunochemical studies suggested that not all mite allergens are of an excretory/secretory origin, but some (e.g., Dpt 1, 3, 4, 7, and 31) are derived from the whole mite per se.

Allergens↗